Page last updated: 2024-10-28

hydroxyurea and Local Neoplasm Recurrence

hydroxyurea has been researched along with Local Neoplasm Recurrence in 76 studies

Research Excerpts

ExcerptRelevanceReference
"Previous in vitro and in vivo results suggested that hydroxyurea (HU) and verapamil could suppress meningioma growth individually and synergistically."9.22Combined Hydroxyurea and Verapamil in the Clinical Treatment of Refractory Meningioma: Human and Orthotopic Xenograft Studies. ( Barth, T; Burt, L; Dunson, W; Gillespie, DL; Hoang, N; Jensen, RL; Karsy, M, 2016)
"Hydroxyurea (HU) is among the most widely used salvage therapies in progressive meningiomas."9.22Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). ( Brandes, A; Eoli, M; Faedi, M; Franceschi, E; Lombardi, G; Mazza, E; Reni, M; Zanon, S, 2016)
"We prospectively evaluated the efficacy and safety of imatinib plus hydroxyurea in patients with progressive/recurrent meningioma."9.16Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. ( Coan, A; Desjardins, A; Drappatz, J; Friedman, HS; Gururangan, S; Herndon, JE; Lipp, ES; McLendon, RE; Norden, AD; Norfleet, JA; Peters, KB; Reardon, DA; Sampson, JH; Vredenburgh, JJ; Wen, PY, 2012)
"Although tumor regression appears uncommon, these results indicate that hydroxyurea may arrest progression of unresectable or recurrent benign meningiomas."9.10Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. ( Abrey, LE; Cruz, CR; Gentili, F; Hariharan, S; Macdonald, DR; Mason, WP, 2002)
"In this paper the authors present the first evidence that meningiomas respond to treatment with hydroxyurea."9.08Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. ( Anders, M; Fahlbusch, R; Kiesewetter, F; Koch, UH; Marschalek, R; Rittig, MG; Schrell, UM, 1997)
"To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma."8.95Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017)
"The aim of this study was to evaluate the efficacy and toxicity profile of the cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine (CHAMOC) regimen in the treatment of high-risk gestational trophoblastic neoplasia (GTN)."7.81Cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine in the treatment of gestational trophoblastic neoplasia. ( Chan, KK; Chu, MM; Ma, Y; Ngan, HY; Tse, KY, 2015)
"Hydroxyurea (HU), an orally administered chemotherapy, has become the de facto standard therapeutic agent in patients with surgically and radiation refractory meningiomas based on a limited literature."7.77Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series. ( Chamberlain, MC; Johnston, SK, 2011)
"Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy."7.69Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996)
"Forty-seven patients with medulloblastoma were treated postoperatively with procarbazine, followed by craniospinal radiation therapy in combination with hydroxyurea."7.67Treatment of medulloblastoma with procarbazine, hydroxyurea, and reduced radiation doses to whole brain and spine. ( Davis, RL; Edwards, MS; Fulton, D; Levin, VA; Liu, HC; Rodriguez, LA; Silver, P; Wara, W; Wilson, CB, 1988)
"Twenty-one patients with recurrent malignant central nervous system gliomas were treated with a combination of 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine."7.67Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. ( Edwards, MS; Fulton, D; Levin, V; Prados, M; Rodriguez, LA; Silver, P, 1988)
"4 Gy) and concurrent HU, administered for a median time of three months with a daily dosage of 20 mg/kg."6.43Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. ( Fahlbusch, R; Ganslandt, O; Grabenbauer, GG; Hahn, BM; Sauer, R; Schrell, UM, 2005)
"Hydroxyurea was given orally at an initial dose of 20 mg/kg/day (escalated up to 30 mg/kg/day as necessary, if well tolerated)."5.51Evidence of hydroxyurea activity in children with pretreated desmoid-type fibromatosis: A new option in the armamentarium of systemic therapies. ( Affinita, MC; Bisogno, G; Casanova, M; Chiaravalli, S; Corradini, N; Ferrari, A; Meazza, C; Orbach, D, 2019)
"Hydroxyurea was well tolerated although two patients ceased therapy because of skin rashes."5.31Treatment of high risk or recurrent meningiomas with hydroxyurea. ( Ashley, DL; Cher, L; Rosenthal, MA, 2002)
"Short-term treatment of meningioma cell cultures with hydroxyurea for 24 to 48 hours resulted in discrete oligonucleosomal fragments (DNA ladder), another characteristic sign of apoptosis."5.30Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. ( Anders, M; Fahlbusch, R; Kiesewetter, F; Koch, UH; Marschalek, R; Rittig, MG; Schrell, UM, 1997)
"Previous in vitro and in vivo results suggested that hydroxyurea (HU) and verapamil could suppress meningioma growth individually and synergistically."5.22Combined Hydroxyurea and Verapamil in the Clinical Treatment of Refractory Meningioma: Human and Orthotopic Xenograft Studies. ( Barth, T; Burt, L; Dunson, W; Gillespie, DL; Hoang, N; Jensen, RL; Karsy, M, 2016)
"Hydroxyurea (HU) is among the most widely used salvage therapies in progressive meningiomas."5.22Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). ( Brandes, A; Eoli, M; Faedi, M; Franceschi, E; Lombardi, G; Mazza, E; Reni, M; Zanon, S, 2016)
"We prospectively evaluated the efficacy and safety of imatinib plus hydroxyurea in patients with progressive/recurrent meningioma."5.16Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. ( Coan, A; Desjardins, A; Drappatz, J; Friedman, HS; Gururangan, S; Herndon, JE; Lipp, ES; McLendon, RE; Norden, AD; Norfleet, JA; Peters, KB; Reardon, DA; Sampson, JH; Vredenburgh, JJ; Wen, PY, 2012)
"Although tumor regression appears uncommon, these results indicate that hydroxyurea may arrest progression of unresectable or recurrent benign meningiomas."5.10Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. ( Abrey, LE; Cruz, CR; Gentili, F; Hariharan, S; Macdonald, DR; Mason, WP, 2002)
"In this paper the authors present the first evidence that meningiomas respond to treatment with hydroxyurea."5.08Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. ( Anders, M; Fahlbusch, R; Kiesewetter, F; Koch, UH; Marschalek, R; Rittig, MG; Schrell, UM, 1997)
"To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma."4.95Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017)
"The aim of this study was to evaluate the efficacy and toxicity profile of the cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine (CHAMOC) regimen in the treatment of high-risk gestational trophoblastic neoplasia (GTN)."3.81Cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine in the treatment of gestational trophoblastic neoplasia. ( Chan, KK; Chu, MM; Ma, Y; Ngan, HY; Tse, KY, 2015)
"Hydroxyurea (HU), an orally administered chemotherapy, has become the de facto standard therapeutic agent in patients with surgically and radiation refractory meningiomas based on a limited literature."3.77Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series. ( Chamberlain, MC; Johnston, SK, 2011)
"Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy."3.69Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996)
"Forty-seven patients with medulloblastoma were treated postoperatively with procarbazine, followed by craniospinal radiation therapy in combination with hydroxyurea."3.67Treatment of medulloblastoma with procarbazine, hydroxyurea, and reduced radiation doses to whole brain and spine. ( Davis, RL; Edwards, MS; Fulton, D; Levin, VA; Liu, HC; Rodriguez, LA; Silver, P; Wara, W; Wilson, CB, 1988)
"Twenty-one patients with recurrent malignant central nervous system gliomas were treated with a combination of 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine."3.67Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. ( Edwards, MS; Fulton, D; Levin, V; Prados, M; Rodriguez, LA; Silver, P, 1988)
"Patients with recurrent squamous cell carcinoma or a second primary arising in a previously irradiated field were eligible."2.73Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. ( Ang, KK; Harris, J; Machtay, M; Meredith, R; Rotman, M; Schultz, C; Spanos, W; Spencer, SA; Wheeler, RH, 2008)
"The imatinib mesylate dose was 500 mg twice a day for patients on enzyme inducing anti-epileptic drugs (EIAEDs) and 400 mg once a day for those not on EIAEDs."2.73Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. ( Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Salvado, A; Sampson, JH; Sathornsumetee, S; Vredenburgh, JJ, 2007)
"The purpose of this study was to analyze the tolerance and efficacy of full dose reirradiation combined with chemotherapy in patients with head and neck carcinoma (HNC) with a high risk of recurrence after salvage surgery."2.70Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. ( Bobin, S; Bourhis, J; De Crevoisier, R; Domenge, C; Eschwege, F; Janot, F; Koscielny, S; Luboinski, B; Lusinchi, A; Wibault, P, 2001)
"Thrombocytosis was not found to be a prognostic factor in patients with positive pelvic nodes."2.69The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a Gynecologic Oncology Group study. ( Anderson, LL; Donohue, KA; Heller, PB; Hernandez, E; Stehman, FB, 2000)
"The head and neck cancer program at the University of Chicago has reported encouraging results with concomitant 5-fluorouracil, hydroxyurea, and radiation administered every other week to patients with locally advanced or recurrent disease."2.68Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer. ( Haraf, DJ; List, M; Stenson, K; Vokes, EE; Weichselbaum, RR; Witt, ME, 1997)
"Thirty-nine patients with head and neck cancer were entered into Phase I-II study of simultaneous radiation therapy with continuous infusion fluorouracil at 800 mg/m2/day and escalating doses of hydroxyurea."2.67Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. ( Haraf, DJ; Panje, WR; Vokes, EE; Weichselbaum, RR, 1991)
"4 Gy) and concurrent HU, administered for a median time of three months with a daily dosage of 20 mg/kg."2.43Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. ( Fahlbusch, R; Ganslandt, O; Grabenbauer, GG; Hahn, BM; Sauer, R; Schrell, UM, 2005)
"The common clinical presentations of head and neck cancer include early (stage I or II) disease, locally or regionally advanced (stage III or IV, M0) disease, and recurrent or metastatic disease (< 5% of patients)."2.40Oral 5-FU alternatives for the treatment of head and neck cancer. ( Brockstein, BE; Haraf, DJ; Humerickhouse, R; Vokes, EE, 1998)
"Hydroxyurea was given orally at an initial dose of 20 mg/kg/day (escalated up to 30 mg/kg/day as necessary, if well tolerated)."1.51Evidence of hydroxyurea activity in children with pretreated desmoid-type fibromatosis: A new option in the armamentarium of systemic therapies. ( Affinita, MC; Bisogno, G; Casanova, M; Chiaravalli, S; Corradini, N; Ferrari, A; Meazza, C; Orbach, D, 2019)
"From 09/1991 - 06/2007, 24 high-risk salivary gland cancer patients were treated with surgery, followed by adjuvant chemoradiotherapy for high-risk pathologic features including, perineural involvement, nodal involvement, positive margins, or T3/T4 tumors."1.37Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. ( Blair, EA; Cohen, EE; Haraf, DJ; Pederson, AW; Portugal, L; Salama, JK; Seiwert, T; Stenson, KM; Villaflor, VM; Vokes, EE; Witt, ME, 2011)
"Hydroxyurea was well tolerated although two patients ceased therapy because of skin rashes."1.31Treatment of high risk or recurrent meningiomas with hydroxyurea. ( Ashley, DL; Cher, L; Rosenthal, MA, 2002)
"Short-term treatment of meningioma cell cultures with hydroxyurea for 24 to 48 hours resulted in discrete oligonucleosomal fragments (DNA ladder), another characteristic sign of apoptosis."1.30Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. ( Anders, M; Fahlbusch, R; Kiesewetter, F; Koch, UH; Marschalek, R; Rittig, MG; Schrell, UM, 1997)
"Reirradiation of head and neck cancer with 5-fluorouracil and hydroxyurea offers acceptable acute toxicity and minimal late effects."1.30Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck. ( Beenken, SW; Conner, W; Meredith, RF; Peters, GE; Salter, MM; Smith, J; Spencer, SA; Wheeler, RH, 1999)
"Head and neck cancer locally recurrent after previous irradiation and surgery presents a difficult management problem."1.28Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation. ( Kim, RY; Meredith, RF; Peters, GE; Salter, MM; Spencer, SA; Weppelmann, B; Wheeler, RH, 1992)
"Hydroxyurea is an active single agent in squamous cell cancer of the head and neck."1.28Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer. ( Haraf, DJ; Panje, WR; Schilsky, RL; Vokes, EE; Weichselbaum, RR, 1992)
"Sixty-six patients with advanced head and neck cancer 57 of whom had failed to respond to prior irradiation, were treated according to two protocols."1.26[Chemotherapy of advanced head and neck cancer with a combination of bleomycin, vincristine, methotrexate and hydroxyuree or cis-dichloro-diamino-platinium. Analysis of local and general parameters of prognosis (author's transl)]. ( Asselin, B; Bataini, JP; Brugère, J; Garcia-Giralt, E; Jaulerry, M; Jouve, M; Palangie, T; Pouillart, P, 1980)

Research

Studies (76)

TimeframeStudies, this research(%)All Research%
pre-199026 (34.21)18.7374
1990's18 (23.68)18.2507
2000's18 (23.68)29.6817
2010's13 (17.11)24.3611
2020's1 (1.32)2.80

Authors

AuthorsStudies
Rubin, A1
Haroon, A1
Rao, BK1
Firoz, BF1
Parasramka, S1
Talari, G1
Rosenfeld, M1
Guo, J1
Villano, JL1
Ferrari, A1
Orbach, D1
Affinita, MC1
Chiaravalli, S1
Corradini, N1
Meazza, C1
Bisogno, G1
Casanova, M1
Chu, MM1
Ma, Y1
Tse, KY1
Chan, KK1
Ngan, HY1
Karsy, M1
Hoang, N1
Barth, T1
Burt, L1
Dunson, W1
Gillespie, DL1
Jensen, RL1
Mazza, E1
Brandes, A1
Zanon, S1
Eoli, M1
Lombardi, G1
Faedi, M1
Franceschi, E1
Reni, M1
Dresemann, G2
Weller, M1
Rosenthal, MA2
Wedding, U1
Wagner, W1
Engel, E1
Heinrich, B1
Mayer-Steinacker, R1
Karup-Hansen, A1
Fluge, O1
Nowak, A1
Mehdorn, M1
Schleyer, E1
Krex, D1
Olver, IN1
Steinbach, JP1
Hosius, C1
Sieder, C1
Sorenson, G1
Parker, R1
Nikolova, Z1
Paulsson, J1
Lindh, MB1
Jarvius, M1
Puputti, M1
Nistér, M1
Nupponen, NN1
Paulus, W1
Söderberg, O1
von Deimling, A1
Joensuu, H1
Ostman, A1
Hasselblatt, M1
Chamberlain, MC1
Johnston, SK1
Choe, KS1
Haraf, DJ11
Solanki, A1
Cohen, EE3
Seiwert, TY1
Stenson, KM4
Blair, EA2
Portugal, L3
Villaflor, VM2
Witt, ME5
Vokes, EE12
Salama, JK3
Pederson, AW1
Seiwert, T1
Reardon, DA3
Norden, AD1
Desjardins, A3
Vredenburgh, JJ3
Herndon, JE3
Coan, A2
Sampson, JH2
Gururangan, S3
Peters, KB2
McLendon, RE2
Norfleet, JA1
Lipp, ES2
Drappatz, J1
Wen, PY1
Friedman, HS3
McLendon, R1
Sathornsumetee, S2
Rich, JN2
Janney, D1
Golden, DW1
Rudra, S1
Nwizu, T1
Blair, E1
Mason, WP1
Gentili, F1
Macdonald, DR1
Hariharan, S1
Cruz, CR1
Abrey, LE2
Spencer, S1
Wheeler, R1
Peters, G1
Meredith, R2
Beenken, S1
Nabel, L1
Wooten, A1
Soong, SJ1
Salter, M1
Petti, MC1
Tafuri, A1
Latagliata, R1
Aloe Spiriti, MA1
Montefusco, E1
Mancini, M1
Meloni, G1
Petrucci, MT1
Spadea, A1
Redi, R1
Alimena, G1
Mandelli, F1
Faivre, S1
Marti, A1
Rixe, O1
Janot, F2
Julieron, M1
Gatineau, M1
Temam, S1
Armand, JP1
Domenge, C2
Luboinski, B2
Raymond, E1
Hahn, BM1
Schrell, UM3
Sauer, R1
Fahlbusch, R3
Ganslandt, O1
Grabenbauer, GG1
Chmura, SJ1
Milano, MT1
Kao, J1
Cramer, P1
Thomale, UW1
Okuducu, AF1
Lemke, AJ1
Stockhammer, F1
Woiciechowsky, C1
Quinn, JA1
Friedman, AH1
Provenzale, JM1
Dowell, JM1
Salvado, A1
Shah, GD1
Silver, JS1
Rosenfeld, SS1
Gavrilovic, IT1
Lassman, AB1
Spencer, SA3
Harris, J1
Wheeler, RH3
Machtay, M1
Schultz, C1
Spanos, W1
Rotman, M1
Ang, KK1
Stehlin, JS1
Hills, WJ1
Rufino, C1
Pouillart, P1
Palangie, T1
Garcia-Giralt, E1
Jouve, M1
Bataini, JP1
Jaulerry, M1
Brugère, J1
Asselin, B1
Vogl, SE1
Camacho, F1
Kaplan, BH1
Lerner, H1
Cinberg, J1
Hill, GJ1
Krementz, ET1
Hill, HZ1
Schmidt, JD1
Scott, WW1
Gibbons, R1
Johnson, DE1
Prout, GR1
Loening, S1
Soloway, M1
deKernion, JB1
Pontes, JE1
Slack, NH1
Murphy, GP2
Shields, TW1
Higgins, GA1
Humphrey, EW1
Matthews, MJ1
Keehn, RJ1
Levin, VA5
Wilson, CB2
Vestnys, PS1
Stenson, K3
Stupp, R1
Malone, D1
Levin, J1
Weichselbaum, RR6
Sneed, PK1
Gutin, PH1
Larson, DA1
Malec, MK1
Phillips, TL1
Prados, MD2
Scharfen, CO1
Weaver, KA1
Wara, WM1
Currie, JL1
Blessing, JA1
McGehee, R1
Soper, JT1
Berman, M1
Kyritsis, AP1
Yung, WK1
Jaeckle, KA1
Bruner, J1
Gleason, MJ1
Ictech, SE1
Flowers, A1
List, M2
Rittig, MG2
Anders, M2
Kiesewetter, F2
Marschalek, R2
Koch, UH2
Cusimano, MD1
Brockstein, BE1
Humerickhouse, R1
Peters, GE2
Beenken, SW1
Meredith, RF2
Smith, J1
Conner, W1
Salter, MM2
Haie-Meder, C1
Fervers, B1
Chauvergne, J1
Fondrinier, E1
Lhommé, C1
Guastalla, JP1
Resbeut, M1
Schaefer, U1
Micke, O1
Schueller, P1
Willich, N1
Hernandez, E1
Donohue, KA1
Anderson, LL1
Heller, PB1
Stehman, FB1
Kies, MS1
Rosen, F1
Brockstein, B1
Chung, T1
Mittal, BB1
Pelzer, H1
Rademaker, A1
Weichselbaum, R1
De Crevoisier, R1
Wibault, P1
Koscielny, S1
Lusinchi, A1
Bobin, S1
Eschwege, F1
Bourhis, J1
Fiorillo, A1
Maggi, G1
Martone, A1
Migliorati, R1
D'Amore, R1
Alfieri, E1
Greco, N1
Cirillo, S1
Marano, I1
Maury, S1
Belhadj, K1
Chami, I1
Kuentz, M1
Cordonnier, C1
Bories, D1
Wassmann, B1
Klein, SA1
Scheuring, U1
Pfeifer, H1
Martin, H1
Gschaidmeier, H1
Hoelzer, D1
Ottmann, OG1
Ashley, DL1
Cher, L1
Kapoor, N1
Keever, CA1
Hsu, SH1
Copelan, EA1
Tutschka, PJ1
McGinn, CJ1
Kinsella, TJ1
Weppelmann, B1
Kim, RY1
Panje, WR3
Schilsky, RL2
Abele, R1
Honegger, HP1
Grossenbacher, R1
Mermillod, B1
Kaplan, E1
Gervasi, A1
Wolfensberger, M1
Lehmann, W1
Cavalli, F1
Grant, HR1
Clifford, P1
Piver, M1
Khalil, M1
Emrich, LJ1
Belani, CP1
Eisenberger, M1
Van Echo, D1
Hiponia, D1
Aisner, J1
Pendergrass, TW1
Milstein, JM1
Geyer, JR1
Mulne, AF1
Kosnik, EJ1
Morris, JD1
Heideman, RL1
Ruymann, FB1
Stuntz, JT1
Bleyer, WA1
Moran, WJ1
Awan, AM1
Guarnieri, CM1
Rodriguez, LA2
Edwards, MS2
Wara, W1
Liu, HC1
Fulton, D2
Davis, RL1
Silver, P2
Prados, M1
Levin, V1
Bezwoda, WR1
Nissenbaum, M1
Derman, DP1
Abdi, EA1
Hanson, J1
McPherson, TA1
Simmonds, WP1
Stephens, FO1
Watne, AL1
Covey, TH1
Carter, SK1
Smith, JP1
Rutledge, F1
Burns, BC1
Soffar, S1
Hussey, DH1
Samuels, ML1
Kaufman, JJ1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Combination of Hydroxyurea and Verapamil for Refractory Meningiomas[NCT00706810]Phase 28 participants (Actual)Interventional2007-12-31Completed
A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma[NCT00354913]Phase 221 participants (Actual)Interventional2005-05-31Completed
Phase I/II Dose Escalation Trial of Induction and Concomitant Erlotinib and Celecoxib With Radiation Therapy for Treatment of Poor Prognosis Head and Neck Cancer, Including Reirradiation[NCT00970502]Phase 1/Phase 215 participants (Actual)Interventional2007-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Median Progression-free Survival Rates of the Treatment Population.

Response and progression will be evaluated in this study using measurements from the MRI/CT scans. Measurements will be made of the image slice with the largest cross sectional area. Two orthogonal measures will be made to determine maximal AP and lateral dimensions. Progression of disease will be defined as a greater than 25% increase of largest cross sectional area by two orthogonal measurements, taking as reference the smallest sum recorded since the treatment started or the appearance of one or more new lesions. (NCT00706810)
Timeframe: 31 months

Interventionmonths (Median)
All Participants8.0

Number of Participants Experiencing Serious Adverse Events Including But Not Limited to Hospitalizations, Deaths Related to Treatment, or Other Incapacitating Conditions.

Adverse Events assessed in accordance with CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 3.0. (NCT00706810)
Timeframe: two years

Interventionparticipants (Number)
All Groups0

Median Overall Survival (OS)

Time in months from the start of study treatment to date of death due to any cause. Patients alive at last follow-up are censored as of that follow-up date. Median OS was estimated using a Kaplan-Meier curve. (NCT00354913)
Timeframe: From the date of study treatment initiation to the date of death from any cause, assessed up to 69 months.

Interventionmonths (Median)
Imatinib Mesylate+Hydroxyurea66

Median Progression-free Survival (PFS)

Time in months from the start of study treatment to the date of first progression according to Macdonald criteria, or to death due to any cause. Patients alive who had not progressed as of the last follow-up had PFS censored at the last follow-up date. Median PFS was estimated using a Kaplan-Meier curve. (NCT00354913)
Timeframe: From the date of study treatment initiation to the date of the first documented progression or death from any cause, whichever came first, assessed up to 69 months.

Interventionmonths (Median)
Imatinib Mesylate+Hydroxyurea7

Objective Response Rate

Percentage of participants with an objective response (complete response or partial response). Per modified Macdonald criteria and assessed by MRI, complete response (CR) was the disappearance of all target lesions and partial response (PR) was a ≥50% decrease in the sum of the longest diameter of target lesions. Objective response = CR+PR. (NCT00354913)
Timeframe: 69 Months

Interventionpercentage of participants (Number)
Imatinib Mesylate+Hydroxyurea0

Progression-free Survival at 6 Months

Percentage of participants surviving six months from the start of study treatment without progression of disease. PFS was defined as the time from the date of study treatment initiation to the date of the first documented progression according to the Macdonald criteria, or death due to any cause. (NCT00354913)
Timeframe: From the date of study treatment initiation to the date of the first documented progression or death from any cause, whichever came first, assessed up to 69 months. For each participant, PFS was assessed at 6 months after treatment initiation.

Interventionpercentage of participants (Number)
Imatinib Mesylate+Hydroxyurea61.9

Toxicity

Number of participants with acute and late toxicity (NCT00970502)
Timeframe: 30 DAYS

Interventionparticipants (Number)
Celecoxib 200mg0
Celecoxib 400mg1
Celecoxib 600mg2

Clinical Response

Response to Concurrent Erlotinib, Celecoxib, and Reirradiation according to Response Evaluation Criteria in Solid Tumors - Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions (NCT00970502)
Timeframe: 20 months

InterventionParticipants (Count of Participants)
Complete Response(CR)Pathologic partial response (pPR)Progressive disease (PD)No evidence of disease (NED)
Erlotinib + Celecoxib6152

Locoregional Control, Progression-free Survival, Overall Survival and Late Toxicity

At a median follow-up of 11 months, the 1 year locoregional control, progression-free survival, and overall survival rates. (NCT00970502)
Timeframe: 1 year

Interventionpercentage of participants (Number)
locoregional controlprogress-free survivaloverall survival rateslong term toxicity
Erlotinib + Celecoxib6037550

Locoregional Progression

Patients with locoregional and/or distant progression (NCT00970502)
Timeframe: 20 months

Interventionparticipants (Number)
free of diseaseisolated locoregional progressionisolated distant progressionboth locoregional and distant progressionno evidence of disease, died of comorbid illness
Erlotinib + Celecoxib44213

Reviews

7 reviews available for hydroxyurea and Local Neoplasm Recurrence

ArticleYear
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
    The Cochrane database of systematic reviews, 2017, 07-26, Volume: 7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Dis

2017
Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study.
    Journal of neuro-oncology, 2005, Volume: 74, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Disease Progres

2005
The role of paclitaxel in the treatment of head and neck cancer.
    Seminars in oncology, 1995, Volume: 22, Issue:5 Suppl 12

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined

1995
Oral 5-FU alternatives for the treatment of head and neck cancer.
    Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:10 Suppl 7

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

1998
[Standards, options and recommendations: concomitant radiochemotherapy for cancer of the cervix: a critical analysis of the literature and update of SOR].
    Bulletin du cancer, 1999, Volume: 86, Issue:10

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic

1999
The experimental and clinical rationale for the use of S-phase-specific radiosensitizers to overcome tumor cell repopulation.
    Seminars in oncology, 1992, Volume: 19, Issue:4 Suppl 11

    Topics: Animals; Cell Division; Fluorouracil; Humans; Hydroxyurea; Neoplasm Recurrence, Local; Neoplasms; Ra

1992
Chemotherapy of primary brain tumors.
    Neurologic clinics, 1985, Volume: 3, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Brain Stem; Child; Efl

1985

Trials

27 trials available for hydroxyurea and Local Neoplasm Recurrence

ArticleYear
Combined Hydroxyurea and Verapamil in the Clinical Treatment of Refractory Meningioma: Human and Orthotopic Xenograft Studies.
    World neurosurgery, 2016, Volume: 86

    Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biologi

2016
Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans;

2016
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.
    Journal of neuro-oncology, 2010, Volume: 96, Issue:3

    Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Brai

2010
Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma.
    International journal of cancer, 2011, Apr-15, Volume: 128, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Drug Resistance, Neopla

2011
Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
    Journal of neuro-oncology, 2012, Volume: 106, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease

2012
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
    Cancer, 2012, Oct-01, Volume: 118, Issue:19

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother

2012
Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma.
    Journal of neurosurgery, 2002, Volume: 97, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Female; Humans; Hydroxyurea; Karnofsky Perf

2002
Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer.
    Head & neck, 2003, Volume: 25, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast

2003
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
    Journal of neuro-oncology, 2007, Volume: 83, Issue:1

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Benzamide

2007
Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas.
    Journal of neuro-oncology, 2007, Volume: 85, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Bone Marrow Di

2007
Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.
    Head & neck, 2008, Volume: 30, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous

2008
Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A).
    Cancer, 1984, Mar-15, Volume: 53, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; D

1984
Prolonged intermittent adjuvant chemotherapy with CCNU and hydroxyurea after resection of carcinoma of the lung.
    Cancer, 1982, Nov-01, Volume: 50, Issue:9

    Topics: Carcinoma; Clinical Trials as Topic; Humans; Hydroxyurea; Lomustine; Lung Neoplasms; Male; Neoplasm

1982
Primary intracranial gliomas: clinical studies and treatment regimens of the Brain Tumor Research Center, University of California, San Francisco, 1977-1979.
    Cancer treatment reports, 1981, Volume: 65 Suppl 2

    Topics: Antineoplastic Agents; Brain Neoplasms; California; Carmustine; Clinical Trials as Topic; Drug Thera

1981
Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost.
    International journal of radiation oncology, biology, physics, 1994, Jul-01, Volume: 29, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain; Brain Neoplasms;

1994
Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study.
    Gynecologic oncology, 1996, Volume: 61, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Etopo

1996
Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F

1996
Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer.
    Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy;

1997
Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
    Journal of neurosurgery, 1997, Volume: 86, Issue:5

    Topics: Adult; Antineoplastic Agents; Female; Humans; Hydroxyurea; Magnetic Resonance Imaging; Male; Meninge

1997
The significance of thrombocytosis in patients with locally advanced cervical carcinoma: a Gynecologic Oncology Group study.
    Gynecologic oncology, 2000, Volume: 78, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Combined Modality Therapy; Disease-Free Survival

2000
Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-01, Volume: 19, Issue:7

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo

2001
Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma.
    Cancer, 2001, Jun-01, Volume: 91, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2001
[Chemotherapy of advanced prostate cancer].
    Voprosy onkologii, 1977, Volume: 23, Issue:12

    Topics: Chlorambucil; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Diethylstilbestrol; Drug Eval

1977
Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer.
    American journal of clinical oncology, 1991, Volume: 14, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc

1991
A randomized study of methotrexate, bleomycin, hydroxyurea with versus without cisplatin in patients with previously untreated and recurrent squamous cell carcinoma of the head and neck.
    European journal of cancer & clinical oncology, 1987, Volume: 23, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci

1987
Hydroxyurea plus pelvic irradiation versus placebo plus pelvic irradiation in nonsurgically staged stage IIIB cervical cancer.
    Journal of surgical oncology, 1989, Volume: 42, Issue:2

    Topics: Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Combined Modality Therapy; Double-Blind Method; Fe

1989
Treatment of metastatic and recurrent cervix cancer with chemotherapy: a randomised trial comparing hydroxyurea with cisdiamminedichloro-platinum plus methotrexate.
    Medical and pediatric oncology, 1986, Volume: 14, Issue:1

    Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trial

1986

Other Studies

42 other studies available for hydroxyurea and Local Neoplasm Recurrence

ArticleYear
Utility of Optical Imaging in a Patient With Recurrent, Multifocal Hydroxyurea-Associated Basal Cell Carcinoma.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2022, Jan-01, Volume: 48, Issue:1

    Topics: Carcinoma, Basal Cell; Female; Head and Neck Neoplasms; Humans; Hydroxyurea; Middle Aged; Neoplasm R

2022
Evidence of hydroxyurea activity in children with pretreated desmoid-type fibromatosis: A new option in the armamentarium of systemic therapies.
    Pediatric blood & cancer, 2019, Volume: 66, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Disease Progression; Female; Fibr

2019
Cyclophosphamide, hydroxyurea, actinomycin D, methotrexate, and vincristine in the treatment of gestational trophoblastic neoplasia.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015, Volume: 25, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dactinomycin; Female; Gesta

2015
Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series.
    Journal of neuro-oncology, 2011, Volume: 104, Issue:3

    Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Disease-Free Survival; Drug Administrati

2011
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.
    Cancer, 2011, Oct-15, Volume: 117, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Antineoplastic Combined Chemotherapy Protocols; Ch

2011
Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies.
    Head & neck oncology, 2011, Jul-26, Volume: 3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female; Fl

2011
Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma.
    Oral oncology, 2013, Volume: 49, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom

2013
High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias.
    Annals of hematology, 2003, Volume: 82, Issue:8

    Topics: Adult; Antineoplastic Agents; Bone Marrow Transplantation; Cytogenetic Analysis; Dose-Response Relat

2003
Preoperative sequential chemotherapy in locally advanced squamous cell carcinoma of the head and neck.
    Head & neck, 2005, Volume: 27, Issue:4

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An

2005
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
    International journal of radiation oncology, biology, physics, 2006, Feb-01, Volume: 64, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality

2006
An atypical spinal meningioma with CSF metastasis: fatal progression despite aggressive treatment. Case report.
    Journal of neurosurgery. Spine, 2005, Volume: 3, Issue:2

    Topics: Adult; Antineoplastic Agents; Cervical Vertebrae; Decompression, Surgical; Disease Progression; Fata

2005
Disseminated melanoma. Biologic behavior and treatment.
    Archives of surgery (Chicago, Ill. : 1960), 1967, Volume: 94, Issue:4

    Topics: Antineoplastic Agents; Chlorambucil; Cyclophosphamide; Dactinomycin; Fluorouracil; Humans; Hydrazine

1967
[Chemotherapy of advanced head and neck cancer with a combination of bleomycin, vincristine, methotrexate and hydroxyuree or cis-dichloro-diamino-platinium. Analysis of local and general parameters of prognosis (author's transl)].
    Bulletin du cancer, 1980, Volume: 67, Issue:3

    Topics: Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Head and Neck

1980
Hydroxyurea fails to improve the results of MBD chemotherapy in cancer of the head and neck, but reduces toxicity.
    Cancer, 1983, Dec-01, Volume: 52, Issue:11

    Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Drug

1983
Chemotherapy programs of the National Prostatic Cancer Project (NPCP).
    Cancer, 1980, Apr-15, Volume: 45, Issue:7 Suppl

    Topics: Antineoplastic Agents; Cyclophosphamide; Dacarbazine; Diethylstilbestrol; Drug Evaluation; Drug Ther

1980
Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.
    Neurosurgery, 1996, Volume: 39, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Pr

1996
Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway.
    Journal of neurosurgery, 1997, Volume: 86, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; DNA Fragmentation; Dose-Respon

1997
Hydroxyurea for treatment of meningioma.
    Journal of neurosurgery, 1998, Volume: 88, Issue:5

    Topics: Antineoplastic Agents; Humans; Hydroxyurea; Meningeal Neoplasms; Meningioma; Neoplasm Recurrence, Lo

1998
Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck.
    American journal of clinical oncology, 1999, Volume: 22, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo

1999
Recurrent head and neck cancer: retreatment of previously irradiated areas with combined chemotherapy and radiation therapy-results of a prospective study.
    Radiology, 2000, Volume: 216, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P

2000
Shunt-related abdominal metastases in an infant with medulloblastoma: long-term remission by systemic chemotherapy and surgery.
    Journal of neuro-oncology, 2001, Volume: 52, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cerebellar Neoplasms; Combi

2001
Autologous reconstitution combined with durable leukemic remission after allogeneic BMT for CML: absence of persistence of a donor-derived T cell effector population.
    Bone marrow transplantation, 2001, Volume: 28, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Bone Marrow T

2001
Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation.
    Bone marrow transplantation, 2001, Volume: 28, Issue:7

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bone Marrow Transplantation; C

2001
Treatment of high risk or recurrent meningiomas with hydroxyurea.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2002, Volume: 9, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Exanthema; Female; Humans; Hydroxyurea; Male; Meningeal Neoplasm

2002
Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Cycle

1992
Prolonged remission of accelerated phase Philadelphia chromosome negative chronic myeloid leukemia following autologous recovery of normal hematopoietic elements after busulfan/cyclophosphamide and allogeneic marrow transplantation.
    Bone marrow transplantation, 1992, Volume: 9, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantat

1992
Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation.
    International journal of radiation oncology, biology, physics, 1992, Volume: 22, Issue:5

    Topics: Adult; Aged; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Head and

1992
Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer.
    Seminars in oncology, 1992, Volume: 19, Issue:3 Suppl 9

    Topics: Administration, Oral; Bone Marrow; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Fluorouracil; H

1992
Postcricoid carcinoma: a retrospective study of 13 patients.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1985, Volume: 11, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Co

1985
Phase II study of caracemide in advanced or recurrent non-small cell lung cancer.
    Cancer treatment reports, 1987, Volume: 71, Issue:11

    Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis-Related Groups; Drug Evaluation; Female; Huma

1987
Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Cisplatin; Comb

1987
Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 1988, Volume: 98, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy;

1988
Treatment of medulloblastoma with procarbazine, hydroxyurea, and reduced radiation doses to whole brain and spine.
    Journal of neurosurgery, 1988, Volume: 68, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain; Cerebellar Neoplasms; Child; Comb

1988
Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine.
    Neurosurgery, 1988, Volume: 22, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem; Chil

1988
Adjuvant chemoimmunotherapy after regional lymphadenectomy for malignant melanoma.
    American journal of clinical oncology, 1987, Volume: 10, Issue:2

    Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carmustine; Com

1987
Chemotherapy in recurrent heat and neck cancer.
    Otolaryngologic clinics of North America, 1974, Volume: 7, Issue:1

    Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Cytarabine; Drug Thera

1974
Combined chemotherapy, radiotherapy, and surgery in the treatment of advanced but localized solid malignant tumours.
    The Australian and New Zealand journal of surgery, 1974, Volume: 44, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cystadenocarcinoma; Drug Th

1974
Hormones, chemotherapy, and the breast cancer patient.
    Oncology, 1972, Volume: 26, Issue:2

    Topics: Administration, Oral; Adrenalectomy; Adult; Aged; Breast Neoplasms; Cyclophosphamide; Female; Fluoro

1972
Some thoughts on surgical adjuvant studies in lung cancer.
    Cancer chemotherapy reports. Part 3, 1973, Volume: 4, Issue:2

    Topics: Alkylating Agents; Antineoplastic Agents; Carcinoma, Bronchogenic; Cyclophosphamide; Drug Combinatio

1973
Systemic chemotherapy for carcinoma of the cervix.
    American journal of obstetrics and gynecology, 1967, Mar-15, Volume: 97, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Fema

1967
Combined hydroxyurea and radiotherapy: a new dosage schedule.
    Southern medical journal, 1972, Volume: 65, Issue:2

    Topics: Adult; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Head; Head and Neck Neoplasms;

1972
Treatment of carcinoma of the bladder with combined radiotherapy, chemotherapy, and surgery.
    Archives of surgery (Chicago, Ill. : 1960), 1969, Volume: 99, Issue:4

    Topics: Animals; Cricetinae; Female; Fluorouracil; Humans; Hydroxyurea; Male; Mitomycins; Neoplasm Metastasi

1969
chemdatabank.com